Semaglutide and tirzepatide share two common substitutions, one is Aib at the second N-terminal residue and the other is acylated lysine at the 20 th N-terminal residue by C18 diacid via a Glu-2OEG linker, to reduce degradation by dipeptidyl peptidase-4 (DPP-4) and to prolong their half-lives by enhanced binding to plasma albumin (Fig
CAS 214047-00-4View product Healing & RecoveryVerified batchBPC 157PriceFrom $30.99Formats4 sizes Compare size options, price, and certificate status before opening the product record
It can also connect food with CGM glucose data when available
Many competing services require in-person appointments, IV clinic visits, or complicated onboarding steps that limit scalability
1,4,5 Tirzepatide licensing and funding context Licensing: Although tirzepatide is not licensed for the treatment of type 1 diabetes, it can be prescribed to adults with type 1 diabetes when obesity is the primary indication, provided they meet the MHRA-approved criteria for weight management (BMI 30 kg/m 2 , or BMI 2729.9 kg/m 2 with at least one weight-related health problem)